Capital Planning Advisors LLC boosted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 31.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,809 shares of the biopharmaceutical company’s stock after buying an additional 1,634 shares during the quarter. Capital Planning Advisors LLC’s holdings in Celgene were worth $993,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Thompson Davis & CO. Inc. increased its holdings in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Arcadia Investment Management Corp MI increased its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Guidant Wealth Advisors purchased a new position in Celgene during the third quarter valued at approximately $119,000. Motco increased its holdings in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Celgene during the second quarter valued at approximately $129,000. 79.85% of the stock is currently owned by institutional investors.

Several brokerages recently issued reports on CELG. BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a report on Saturday. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $104.00 price target on shares of Celgene in a report on Thursday. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 price target on the stock in a report on Wednesday. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Wednesday. Finally, Mizuho reaffirmed a “buy” rating and issued a $128.00 price target on shares of Celgene in a report on Wednesday. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $129.98.

Shares of Celgene Co. (NASDAQ:CELG) opened at $102.65 on Friday. The firm has a market cap of $81,560.00, a price-to-earnings ratio of 24.21, a PEG ratio of 0.65 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.58 earnings per share. analysts predict that Celgene Co. will post 6.7 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Capital Planning Advisors LLC Raises Position in Celgene Co. (CELG)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2018/01/21/capital-planning-advisors-llc-raises-position-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.